AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01481077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Sustained release for 12 weeks
Study NCT01150565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS low dose and LiRIS high dose
Description: Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Standard of Care
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Standard of Care
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ETOPOSIDE
Description: Standard of Care
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HYDROCORTISONE
Description: Standard of Care
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LEUCOVORIN CALCIUM
Description: Standard of Care
Study NCT03635242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental. Therapeutic program
Description: People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform
Study NCT02545426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change the dialysate calcium concentration
Description: The dialysate calcium concentration will be changed according to the prior concentration
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Description: Standard of Care
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: METHOTREXATE
Description: Standard of Care
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NELARABINE
Description: Standard of Care
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Standard of Care
Study NCT04697199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri Oral Drops
Description: Subgingival delivery of probiotic suspension
Study NCT04697199 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing using hand and ultrasonic instruments
Study NCT04697199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing using hand and ultrasonic instruments
Study NCT00412555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir [Tamiflu]
Description: 30-75mg po daily for 6 weeks
Study NCT02500849 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728mR-HSPC Infusion 3 days following busulfan conditioning
Study NCT02990325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 150mg
Description: ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
Study NCT02990325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 50mg
Description: ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
Study NCT02990325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 50mg
Description: ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
Study NCT00422942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15
Study NCT00422942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg po weekly
Study NCT01207427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01207427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01207427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5945 0.1 mg
Study NCT01207427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5945 0.25 mg
Study NCT01767844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
Study NCT01767844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02052180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
Study NCT02052180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine (Control)
Description: 15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
Study NCT01928758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content Cigarettes
Description: Research cigarettes will have gradually reduced nicotine content
Study NCT01928758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual Nicotine Content Cigarettes
Description: Usual Nicotine Content Cigarettes
Study NCT01331876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral Therapy
Description: 15 CBT sessions with a psychologist expert in OCD treatment
Study NCT01026558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: Ceftobiprole, 500 mg as single iv infusion over 2 hours
Study NCT01026558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftobiprole
Description: Ceftobiprole, 500 mg as single iv infusion over 2 hours
Study NCT02354027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824 metformin
Description: Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin
Study NCT01378624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies.
Study NCT04218942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter
Description: Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output.
Study NCT05025306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziziphus honey
Description: ziziphus honey obtained form ziziphus spina-christi trees also called sidr tree
Study NCT02033486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOBI + DBT
Study NCT01912482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory training
Description: The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
Study NCT01912482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ventilatory training
Description: The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
Study NCT02186145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of metronidazole; nystatin and dexamethasone
Study NCT02186145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Vaginal cream of metronidazole and nystatin
Study NCT01442766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
Study NCT01442766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
Study NCT03434106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposic
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
Study NCT01241903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
Study NCT01241903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: frequency and duration
Study NCT01164449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space TGC
Description: Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
Study NCT02877784 — intervention group
Intervention type: PROCEDURE
Intervention: Videofluoroscopic swallowing study
Description: Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
Study NCT02877784 — intervention group
Intervention type: OTHER
Intervention: Functional Oral Intake Scale
Description: The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
Study NCT02877784 — intervention group
Intervention type: OTHER
Intervention: Eating Assessment Tool-10
Description: The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
Study NCT01870310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterised renal denervation
Study NCT03697681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
Study NCT03697681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl (normal saline)
Description: The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
Study NCT02841462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-bursal thermal ablation
Description: A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
Study NCT02572765 — intervention group
Intervention type: OTHER
Intervention: PET/CT scan
Description: PET/CT scan
Study NCT03332446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold water immersion
Description: 10 min at 12-15°C
Study NCT03075709 — intervention group
Intervention type: OTHER
Intervention: Clinical Pathway (CPW)
Description: CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
Study NCT00364741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: During and 2 hours after surgery
Study NCT00627133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: 2 gram iv load, 500mg bid
Study NCT01500486 — intervention group
Intervention type: DEVICE
Intervention: NordiFlex PenMate™
Description: Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
Study NCT03899987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO
Study NCT03899987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT03899987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT03899987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV
Study NCT03899987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study NCT02391519 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of myometrial, cord blood, and placental tissue samples
Description: We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
Study NCT02235545 — intervention group
Intervention type: DEVICE
Intervention: St. Jude Medical Optisure Lead
Description: Patients implanted with St. Jude Medical Optisure Lead
Study NCT02338700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV
Description: MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
Study NCT02338700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study NCT02338700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study NCT02815644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin/linagliptin FDC
Description: empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
Study NCT02715986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI
Description: Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
Study NCT02604914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612
Description: Subcutaneous solution
Study NCT02604914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCIG
Description: Intrajejunal Gel
Study NCT03021772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
Study NCT03434106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes
Study NCT03979352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: Treatment with empagliflozin 25mg orally once a day
Study NCT03021772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
Study NCT02556060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamotrigine
Description: Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
Study NCT02556060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
Study NCT02556060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosing schedule as study drug
Study NCT02556060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Same dosing schedule as study drug
Study NCT03979352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: artificial pancreas
Description: Insulin delivery via a closed loop single-hormone artificial pancreas system.
Study NCT01123395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine 0.6 mg tablet
Description: One Colcrys® 0.6 mg intact tablet taken by mouth
Study NCT01123395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine 0.6 mg tablet
Description: One Colcrys® 0.6 mg tablet dissolved in apple juice
Study NCT03485521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The tracheobronchial aspiration
Description: Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure
Study NCT03485521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The tracheobronchial aspiration
Description: Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure
Study NCT00793130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coltect
Description: Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
Study NCT03471741 — intervention group
Intervention type: RADIATION
Intervention: IMRT with concomitant boost
Study NCT03471741 — intervention group
Intervention type: RADIATION
Intervention: 3D-RT with sequential boost
Study NCT02359513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants
Description: bulimic patients are treated during 3 months
Study NCT02359513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: PET scan using \[18F\]MPPF is performed before and after (3 months)antidepressant treatment
Study NCT00422383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
Study NCT02508012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immuno monitoring
Description: treatment optimization
Study NCT00422383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
Study NCT00422383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182